Aventis Continues Fight Over Generic Allegra

Law360, New York (August 13, 2007, 12:00 AM EDT) -- Aventis Pharmaceuticals Inc. has filed suit against generic maker Mylan Pharmaceuticals Inc., as part of its continuing effort to block the sales of generic versions of its prescription antihistamine Allegra.

In a complaint filed Thursday in the U.S. District Court for the Eastern District of Texas, Aventis alleged that Mylan’s generic drugs containing fexofenadine hydrochloride, the active ingredient in Allegra, infringe on its process patent.

The patent, entitled “Processes for Preparing Anhydrous and Hydrate Forms of Antihistaminic Piperidine Derivatives, Polymorphs and Pseudomorphs Thereof,” describes a method...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.